{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:02:12Z","timestamp":1788447732328,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/inf.0000000000001386","type":"journal-article","created":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T13:22:40Z","timestamp":1477747360000},"page":"184-188","source":"Crossref","is-referenced-by-count":6,"title":["Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057"],"prefix":"10.1097","volume":"36","author":[{"given":"Luiz Eduardo","family":"Osorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ines","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newton","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Kreitchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Emel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esau","family":"Joao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Mofenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nielsen-Saines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.clp.2010.08.007","article-title":"Prevention of mother-to-child transmission of HIV: antiretroviral strategies.","volume":"37","author":"Read","year":"2010","journal-title":"Clin Perinatol"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"e1001015","DOI":"10.1371\/journal.pmed.1001015","article-title":"Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding\u2013the Kisumu Breastfeeding Study, Kenya: a clinical trial.","volume":"8","author":"Thomas","year":"2011","journal-title":"PLoS Med"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.aids.0000279708.09180.f5","article-title":"Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.","volume":"21","author":"Palombi","year":"2007","journal-title":"AIDS"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa0911486","article-title":"Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.","volume":"362","author":"Chasela","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMoa0907736","article-title":"Antiretroviral regimens in pregnancy and breast-feeding in Botswana.","volume":"362","author":"Shapiro","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200565030-00006","article-title":"Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.","volume":"65","author":"Lyseng-Williamson","year":"2005","journal-title":"Drugs"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-na\u00efve HIV-1-infected patients.","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"R12-11-20210202","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-11-20210202","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"e74314","DOI":"10.1371\/journal.pone.0074314","article-title":"Safety, adherence and acceptability of intermittent tenofovir\/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.","volume":"8","author":"Kibengo","year":"2013","journal-title":"PLoS One"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/QAD.0b013e3283536b5e","article-title":"Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?","volume":"26","author":"Kuhn","year":"2012","journal-title":"AIDS"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0b013e328352d135","article-title":"Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.","volume":"26","author":"Siberry","year":"2012","journal-title":"AIDS"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042560-200203010-00001","article-title":"Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).","volume":"29","author":"Tarantal","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0736-0266(02)00074-8","article-title":"Tenofovir treatment at 30\u2009mg\/kg\/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).","volume":"20","author":"Castillo","year":"2002","journal-title":"J Orthop Res"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042560-199904010-00001","article-title":"Administration of 9-[2-\u00ae-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.","volume":"20","author":"Tarantal","year":"1999","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.48.5.1469-1487.2004","article-title":"Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.","volume":"48","author":"Van Rompay","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hiv.12123","article-title":"Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.","volume":"15","author":"Bloch","year":"2014","journal-title":"HIV Med"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2012-3686","article-title":"Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.","volume":"98","author":"Cotter","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-11-20210202","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"e32445","DOI":"10.1371\/journal.pone.0032445","article-title":"Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.","volume":"7","author":"Rasmussen","year":"2012","journal-title":"PLoS One"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3851\/IMP1874","article-title":"Bone turnover, osteoprotegerin\/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.","volume":"16","author":"Brown","year":"2011","journal-title":"Antivir Ther"},{"key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R36-11-20210202","first-page":"41","article-title":"Tenofovir-associated bone density loss.","volume":"6","author":"Grigsby","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"e90111","DOI":"10.1371\/journal.pone.0090111","article-title":"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.","volume":"9","author":"Kasonde","year":"2014","journal-title":"PLoS One"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2334-14-131","article-title":"Focal bone lesions in HIV-positive patient treated with tenofovir.","volume":"14","author":"Mangioni","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R40-11-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/00365548.2013.840921","article-title":"Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.","volume":"46","author":"Koenig","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"R41-11-20210202","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1545109710376595","article-title":"Tenofovir-associated severe bone pain: I cannot walk!","volume":"9","author":"Jhaveri","year":"2010","journal-title":"J Int Assoc Physicians AIDS Care (Chic"},{"key":"R42-11-20210202","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1345\/aph.1L083","article-title":"Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.","volume":"42","author":"Nurutdinova","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R43-11-20210202","doi-asserted-by":"crossref","first-page":"e1001217","DOI":"10.1371\/journal.pmed.1001217","article-title":"Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.","volume":"9","author":"Gibb","year":"2012","journal-title":"PLoS Med"},{"key":"R44-11-20210202","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","article-title":"In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.","volume":"16","author":"Vigan\u00f2","year":"2011","journal-title":"Antivir Ther"},{"key":"R45-11-20210202","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.qai.0000184860.62189.c8","article-title":"A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.","volume":"40","author":"Giacomet","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R47-11-20210202","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1016\/j.ajog.2009.10.504","article-title":"Effect of tenofovir on viral suppression during pregnancy in HIV-1 infected women.","volume":"201","author":"Eastwood","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R48-11-20210202","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0b013e3182a7adb2","article-title":"Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.","volume":"64","author":"Ransom","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R49-11-20210202","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/QAD.0b013e328358ccaa","article-title":"Blunted fetal growth by tenofovir in late pregnancy.","volume":"26","author":"Kinai","year":"2012","journal-title":"AIDS"},{"key":"R50-11-20210202","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"R51-11-20210202","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/cid\/cit601","article-title":"Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.","volume":"57","author":"Wang","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R52-11-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","article-title":"Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.","volume":"65","author":"Mirochnick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R54-11-20210202","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy.","volume":"61","author":"Siberry","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R55-11-20210202","first-page":"417","article-title":"[The influence of nutrition and social environment on the bone maturation of children].","volume":"22","author":"Trist\u00e1n Fern\u00e1ndez","year":"2007","journal-title":"Nutr Hosp"},{"key":"R56-11-20210202","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00394-012-0476-4","article-title":"Implications of maternal vitamin D deficiency for the fetus, the neonate and the young infant.","volume":"52","author":"Principi","year":"2013","journal-title":"Eur J Nutr"},{"key":"R57-11-20210202","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/jn\/134.9.2169","article-title":"Maternal nutrition and fetal development.","volume":"134","author":"Wu","year":"2004","journal-title":"J Nutr"},{"key":"R58-11-20210202","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-3476(88)80268-3","article-title":"Osteoporosis in cystic fibrosis.","volume":"113","author":"Gibbens","year":"1988","journal-title":"J Pediatr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:51Z","timestamp":1620954771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201702000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001386","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}